Riskpilot← Back to searchSign inGet full accessTM Ergotest AB
ABActiveOrg 5568349079Domstensv 44Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20100 employees
Revenue 2024
SEK 242K
+50% vs 2023
EBITDA margin
-5.4%
-44% vs 2023
Equity ratio
87.3%
Financial strength
Net profit 2024
SEK -10K
-43% vs 2023
| Revenue | SEK 242K | +50% |
| EBITDA | SEK -13K | -44% |
| Net profit | SEK -10K | -43% |
| Total assets | SEK 283K | -8% |
| Equity | SEK 247K | -4% |
| Employees | 0 | — |
Legal name
TM Ergotest AB
Org number
5568349079
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
21 december 2010
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget ska bedriva sjukvårdsgymnastik och handel med artiklar för sjukvårdsgymnastik jämte därmed förenlig verksamhet.
Address
Domstensv 44
Email
maria.haapalo@outlook.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 229 | 350 | 228 | 161 | 242 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 59 | 38 | 17 | −9 | −13 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 59 | 38 | 17 | −9 | −13 |
| Net financials | −2 | −9 | −6 | 3 | 3 |
| Profit before tax | 58 | 29 | 12 | −7 | −10 |
| Tax | −13 | −7 | −3 | −0 | −0 |
| Net profit | 45 | 22 | 9 | −7 | −10 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 274 | 268 | 298 | 306 | 283 |
| Equity | 234 | 255 | 264 | 257 | 247 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 40 | 12 | 33 | 49 | 36 |
| Total debt | 40 | 12 | 33 | 49 | 36 |
EBITDA margin
-5.4%
This company
15.8%
Market median
-134% vs market
20202024
Equity ratio
87.3%
This company
38.2%
Market median
+129% vs market
20202024
Return on equity
-4.0%
This company
18.4%
Market median
-122% vs market
20202024
Net profit margin
-4.1%
This company
8.1%
Market median
-151% vs market
20202024
Asset turnover
0.86×
This company
1.12×
Market median
+23% vs market
20202024
Debt / equity
0.15×
This company
0.62×
Market median
+76% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
HP | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of TM Ergotest AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hans Peter Wilhelm Otto | Audit | 0 companies |
| Elsa Maria Haapalo | Board of Directors | 0 companies |
| Timo Antero Haapalo | Deputy Board Member | 0 companies |